ArticlePlant physiology2010
The catalytic and protein-protein interaction domains are required for APM1 function.
Article in Plant physiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 9 citations in OpenAlex.
- Broad-range metalloprotease profiling in plants uncovers immunity provided by defence-related metalloenzyme.The New phytologist · 2022Article
- Epigenetics and transcription regulation during eukaryotic diversification: the saga of TFIID.Genes & development · 2019Article
- The Small Molecule Hyperphyllin Enhances Leaf Formation Rate and Mimics Shoot Meristem Integrity Defects Associated with AMP1 Deficiency.Plant physiology · 2016Article
- Suppression of Aβ toxicity by puromycin-sensitive aminopeptidase is independent of its proteolytic activity.Biochimica et biophysica acta · 2013Article
- The role of multifunctional M1 metallopeptidases in cell cycle progression.Annals of botany · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aminopeptidase M1 (APM1) is essential for embryonic, vegetative, and reproductive development in Arabidopsis (Arabidopsis thaliana). Here, we show that, like mammalian M1 proteases, APM1 appears to have distinct enzymatic and protein-protein interaction domains and functions as a homodimer. Arabidopsis seedlings treated with ezetimibe, an inhibitor of M1 protein-protein interactions, mimicked a subset of apm1 phenotypes distinct from those resulting from treatment with PAQ-22, an inhibitor of M1 catalytic activity, suggesting that the APM1 catalytic and interaction domains can function independently. apm1-1 knockdown mutants transformed with catalytically inactive APM1 did not prevent seedling lethality. However, apm1-2 has a functional enzymatic domain but lacks the carboxyl (C) terminus, and transformation with catalytically inactive APM1 rescued the mutant. Overexpression of human insulin-responsive aminopeptidase/oxytocinase rescued all apm1 phenotypes, suggesting that the catalytic activity was sufficient to compensate for loss of APM1 function, while overexpression of catalytically inactive insulin-responsive aminopeptidase/oxytocinase only rescued apm1-2. Increased catalytic activity alone is not sufficient to compensate for loss of APM1 function, as overexpression of another Arabidopsis M1 family member lacking an extended C terminus did not rescue apm1-1. The protein interactions facilitating enzymatic activity appear to be dependent on the C terminus of APM1, as transformation with an open reading frame containing an internal deletion of a portion of the C terminus or a point mutation in a dileucine motif did not rescue the mutant. These results suggest that both the catalytic and interaction domains are necessary for APM1 function but that APM1 function and dimerization do not require these domains to be present in the same linear molecule.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.